Communication of Treatment Options for High-Risk NMIBC

The approval is supported by data from the phase 3 VOLGA trial.

Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.

The recommendation is backed by data from the phase 3 LITESPARK-011 trial.

Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.

Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.

enGene expects to initiate a BLA submission by the end of 2026.

The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.

The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.